

### Exercise of Share Options and Directors' Dealings

Immunodiagnostic Systems Holdings PLC ("the Company"), a leading producer of diagnostic testing kits, announces that on 9 December 2009, certain Directors exercised options over in aggregate 1,134,297 ordinary shares of 2p each in the Company ("Ordinary Shares") and subsequently placed 505,628 ordinary shares in aggregate with a number of institutional investors. Notification was received by the Company yesterday. Application will be made at the earliest practicable opportunity for admission of the new ordinary shares to trading on AIM.

Director	Exercise Price	Number of Shares	
		Approved	Unapproved
Roger Duggan	51p	196,078	137,539
Paul Hailes	51p	196,078	137,539
Anthony Wilks	51p	0	133,446
David Evans	51p	0	333,617

The options were exercised under the Company's Approved Share Option Scheme and the Unapproved Share Option Scheme, save for David Evans' which were exercised under a separate Share Option Agreement.

### Directors' Dealings

Following the exercise of Share Options the Directors disposed of a number of their shares. Following these disposals they are interested in the following shares:

Director	Sale Price	Disposal of Shares	Total Holding following notification	
			Number	% of issued Share Capital
Roger Duggan	605p	80,357	2,476,187	8.97%
Paul Hailes	605p	137,539	1,112,728	4.03%
Anthony Wilks	605p	133,446	58,820	0.21%
David Evans	605p	154,286	522,458	1.89%
Alain Rousseau	605p	35,000	50,584	0.18%

### Total Voting Rights

In accordance with FSA's Disclosure and Transparency Rules, the Company advises that its increased issued share capital comprises 27,615,110 ordinary shares of 2 pence each. The voting rights of all of these shares are identical with each share carrying the right to one vote. The Company holds no ordinary shares in Treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Immunodiagnostic Systems Holdings PLC under the Disclosure and Transparency Rules.

### Contacts:

**Immunodiagnostic Systems Holdings PLC** Tel: 0191 519 0660  
Roger Duggan, CEO  
Paul Hailes, Finance Director

**Brewin Dolphin Investment Banking** Tel: 0845 213 4730  
Andrew Emmott  
Sean Wyndham-Quin

**Walbrook PR Ltd** Tel: 020 7933 8787  
Paul McManus